Table 3.
Summary of meningioma GEMM models.
| Construction | Genetics | Temporal Window of Activation | Phenotype (Grade) | Meningioma Prevalence | Year, Reference |
|---|---|---|---|---|---|
| AdCre; Nf2flox/flox | Nf2 loss | PN2-PN3 | M/F (I) | 29% (TO) 19% (SD) |
2002, [66] |
| AdCre; Nf2flox/flox; Ink4a*/* | Nf2 loss + homozygous P16Ink4a mutation | PN2-PN3 | M/F/T (I) | 38% (TO) 36 % (SD) |
2008, [67] |
| AdCre; Nf2flox/flox; Ink4ab−/− | Nf2 + CDKN2AB loss | PN2-PN3 | 66% (I) 31% (II) 3% (III) |
72% | 2013, [59] |
| PGDSCre; Nf2flox:flox | Nf2 loss in PGDS + cells | E12.5-PN2 | M (I) F (I) |
38% 38% |
2011, [68] |
| PGDSCre; Nf2flox/flox; p16ink4a/− | Nf2 loss + P16ink4a mutation in PGDS + cells | E12.5-PN2 | M (I) F (I) |
50% 50% |
2011, [68] |
| PGDSCre; Nf2flox/flox; p53flox/flox | Nf2 loss + p53 nullizygosity in PGDS + cells | E12.5-PN2 | F (I) | 43% | 2011, [68] |
| PGDStv-a; PDGF-B | PDGF overexpression in PGDS + cells | E12.5-PN2 | (I) | 27% | 2015, [69] |
| PGDStv-a; PDGF-B; AdCre; Nf2flox/flox | PDGF overexpression + Nf2 loss in PGDS + cells | E12.5-PN7 | Grade I (60%) Grade II (40%) |
52% | 2015, [69] |
| PGDStv-a; PDGF-B; AdCre; Nf2flox/flox; Cdkn2ab−/− | PDGF Overexpression + nf2 loss + Cdkn2ab loss | E12.5-PN7 | Grade I (33%) Grade II (47%) Grade III (20%) |
79% | 2015, [69] |
| PDGSCre; SmoM2 | Activating mutation of Smo in PGDS + cells | E12.5-PN2 | M (I) | 21% | 2017, [70] |
Abbreviations: PN: post-natal day; M = meningothelial; F: fibroblastic; T: transitional; TO: transorbital; SD: subdural.